Par Pharmaceutical Companies Inc. has received final approval from the US Food and Drug Administration for the company's abbreviated new drug application for cabergoline tablets.

Cabergoline is the generic version of Pfizer's Dostinex and is used for the treatment of hyperprolactinemic disorders. Annual US sales of Dostinex exceed $80 million. Par will begin shipping cabergoline tablets immediately, states a Par release.

Par Pharmaceutical Companies Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. Par manufactures, markets or licenses more than 90 generic drugs.